KALA BIO (KALA) Competitors $3.53 +0.04 (+1.15%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$3.61 +0.08 (+2.24%) As of 04/15/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. CLYM, ZNTL, VOR, CCCC, PLRX, ANIX, SNTI, CRDL, GALT, and CRVOShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Vor Biopharma (VOR), C4 Therapeutics (CCCC), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Cardiol Therapeutics (CRDL), Galectin Therapeutics (GALT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Climb Bio Zentalis Pharmaceuticals Vor Biopharma C4 Therapeutics Pliant Therapeutics Anixa Biosciences Senti Biosciences Cardiol Therapeutics Galectin Therapeutics CervoMed KALA BIO (NASDAQ:KALA) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations. Does the media refer more to KALA or CLYM? In the previous week, Climb Bio had 1 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.89 beat Climb Bio's score of 0.94 indicating that KALA BIO is being referred to more favorably in the media. Company Overall Sentiment KALA BIO Very Positive Climb Bio Positive Does the MarketBeat Community believe in KALA or CLYM? KALA BIO received 300 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 66.96% of users gave KALA BIO an outperform vote. CompanyUnderperformOutperformKALA BIOOutperform Votes30266.96% Underperform Votes14933.04% Climb BioOutperform Votes2100.00% Underperform VotesNo Votes Do insiders & institutionals have more ownership in KALA or CLYM? 24.6% of KALA BIO shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 8.3% of KALA BIO shares are held by company insiders. Comparatively, 3.2% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, KALA or CLYM? KALA BIO has a beta of -1.71, suggesting that its stock price is 271% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Which has stronger earnings & valuation, KALA or CLYM? Climb Bio has lower revenue, but higher earnings than KALA BIO. Climb Bio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M5.85-$42.20M-$11.03-0.32Climb BioN/AN/A-$35.12M-$2.13-0.64 Is KALA or CLYM more profitable? Climb Bio's return on equity of -42.21% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -448.61% -69.37% Climb Bio N/A -42.21%-41.39% Do analysts recommend KALA or CLYM? KALA BIO currently has a consensus target price of $15.00, suggesting a potential upside of 324.93%. Climb Bio has a consensus target price of $10.00, suggesting a potential upside of 635.29%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryClimb Bio beats KALA BIO on 11 of the 17 factors compared between the two stocks. Remove Ads Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.78M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.286.7921.7317.82Price / Sales5.85225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book1.275.866.464.00Net Income-$42.20M$141.86M$3.20B$247.23M7 Day Performance-8.31%4.50%2.86%1.45%1 Month Performance-46.11%-12.65%-8.55%-6.24%1 Year Performance-48.77%-11.06%10.47%0.60% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.5809 of 5 stars$3.53+1.1%$15.00+324.9%-49.6%$22.78M$3.89M-0.2830Positive NewsGap DownCLYMClimb Bio3.1786 of 5 stars$1.31+2.3%$10.00+663.4%N/A$88.39MN/A-0.629Gap DownZNTLZentalis Pharmaceuticals2.435 of 5 stars$1.22-0.8%$8.24+575.8%-90.4%$87.61M$67.43M-0.49160VORVor Biopharma1.651 of 5 stars$0.69-1.3%$8.86+1,181.8%-61.1%$87.40MN/A-0.42140CCCCC4 Therapeutics2.4537 of 5 stars$1.23-0.8%$12.50+916.3%-82.7%$87.32M$35.58M-0.72150PLRXPliant Therapeutics4.2236 of 5 stars$1.42+6.0%$13.31+837.5%-89.2%$86.96M$1.58M-0.4390Positive NewsANIXAnixa Biosciences2.9188 of 5 stars$2.65+2.7%$9.00+239.6%-9.8%$85.32M$210,000.00-6.795Gap UpSNTISenti Biosciences2.7645 of 5 stars$3.28+0.6%$10.00+204.9%+21.8%$85.29M$2.56M-0.214Short Interest ↑CRDLCardiol Therapeutics1.8048 of 5 stars$1.03+7.6%$8.40+715.5%-40.8%$85.09MN/A-2.6420News CoverageGALTGalectin Therapeutics1.4749 of 5 stars$1.34-0.7%$11.00+720.9%-65.7%$84.66MN/A-1.849Gap DownHigh Trading VolumeCRVOCervoMed3.5627 of 5 stars$9.68+14.0%$27.50+184.1%-58.2%$84.25M$7.14M-4.774Short Interest ↓Gap Up Remove Ads Related Companies and Tools Related Companies Climb Bio Competitors Zentalis Pharmaceuticals Competitors Vor Biopharma Competitors C4 Therapeutics Competitors Pliant Therapeutics Competitors Anixa Biosciences Competitors Senti Biosciences Competitors Cardiol Therapeutics Competitors Galectin Therapeutics Competitors CervoMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALA Stock Free KALA Stock Alerts